• KOL
    • Gastric Cancer
    • Murray, F Brennan
    • Murray, F Brennan: Influence Statistics

      Murray, F Brennan

      Murray, F Brennan

      Show email address

      Memorial Sloan Kettering Cancer Center, New York, NY, USA | Weill Cornell Medical College, New York, NY, USA | From the Gastric and Mixed Tumor Service, Department of Surgery ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Murray F Brennan:Expert Impact

      Concepts for whichMurray F Brennanhas direct influence:Gastric cancer,Soft tissue,Soft tissue sarcoma,Tissue sarcoma,Pancreatic adenocarcinoma,United states,Parenteral nutrition.

      Murray F Brennan:KOL impact

      Concepts related to the work of other authors for whichfor which Murray F Brennan has influence:Gastric cancer,Liver metastases,Soft tissue,Synovial sarcoma,Surgical resection,Gastrointestinal stromal tumors,Lymph node.

      KOL Resume for Murray, F Brennan

      Year
      2022

      Memorial Sloan Kettering Cancer Center, New York, NY, USA

      2021

      Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

      2020

      Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

      Department of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering, New York, NY, USA

      2019

      Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

      2018

      Memorial Sloan Kettering Cancer Center, International Center, 1275 York Avenue, H-1203, New York, NY 10065, USA

      2017

      Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

      2016

      International Center Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA

      Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States

      2015

      Memorial Sloan–Kettering Cancer Center Department of Surgery New York New York

      2014

      Surgery; and

      Department of Surgery Memorial Sloan-Kettering Cancer Center New York, NY allenp@MSKCC.ORG

      2013

      From the Memorial Sloan-Kettering Cancer Center, New York, NY.

      Surgery

      Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, 10065, New York, NY, USA

      2012

      Department of Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

      2011

      Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

      Authors' Affiliations: Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, Illinois; and Department of Surgery, Pathology, Epidemiology and Biostatistics, and Gastroenterology, Memorial Sloan-Kettering Cancer Center, New York, New York

      2010

      Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10065, New York, NY, USA

      2009

      Departments of Epidemiology and Biostatistics, Pathology, and Surgery

      and Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.

      2008

      Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Murray, F Brennan is among the top experts in the world.
      Concept World rank
      levels sarcoma patients #1
      eus laparoscopy #1
      rate clr #1
      futile laparotomy patients #1
      extremity #1
      ppc unresectability #1
      tumorrelated mortality #1
      grc resection #1
      soft tissue sarcoma #1
      glucose oxidation kg1 #1
      treatment sarcoma #1
      nomogram rfs #1
      local recurrence size #1
      insulin protein kinetics #1
      factors r1 resection #1
      surgical resection time #1
      longterm survival decades #1
      fiftythree patients #1
      year sarcoma #1
      patients sporadic mpnst #1
      growth hormone tumor #1
      curative intent gastrectomy #1
      subtype dsd #1
      primary unresectable carcinoma #1
      backgroundsurgery #1
      gastric cancer natural #1
      ppc survival #1
      lesions pancreatic head #1
      surgical systems cancer #1
      site histology #1
      patients repeat #1
      septic cancer #1
      vivo growth hormone #1
      golorectal liver metastases #1
      patients therapeutic intent #1
      iii staging systems #1
      pathologic stage outcome #1
      diseasespecific survival categories #1
      5 reoperation #1
      preoperative assessment risk #1
      staging pancreatic tumors #1
      outcomes1 1no #1
      dss resection #1
      timely cancer surgery #1
      size dss #1
      management emphasis #1
      pancreatic lesions head #1
      enteral feeding ivf #1
      patients adult rhabdomyosarcoma #1
      gastric cancer rate #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Murray, F Brennan

      KOL-Index: 15619

      BACKGROUND: Gastrointestinal stromal tumour is the most common sarcoma of the intestinal tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet-derived growth factor receptor alpha proteins, and is effective in first-line treatment of metastatic gastrointestinal stromal tumour. We postulated that adjuvant treatment with imatinib would improve recurrence-free survival compared with placebo after resection of localised, primary gastrointestinal ...

      Known for Stromal Tumour | Adjuvant Imatinib | Recurrencefree Survival | 1 Year | Patients Placebo
      KOL-Index: 15496

      BACKGROUND: Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop a nomogram to predict RFS after surgery in the absence of adjuvant therapy to help guide patient selection for adjuvant imatinib therapy.

      METHODS: A nomogram to predict RFS based on tumour size (cm), location (stomach, small intestine, colon/rectum, or other), and mitotic index (<5 or > or =5 mitoses per 50 ...

      Known for Prognostic Nomogram | Retrospective Analysis | Surgical Resection | Concordance Probabilities | Gastrointestinal Stromal
      KOL-Index: 15097

      OBJECTIVE: The aim of this study was to determine the pattern of recurrence and prognostic significance of histologic subtype in a large series of patients with primary retroperitoneal liposarcoma.

      SUMMARY BACKGROUND DATA: Classification of liposarcoma into subtypes, based on morphologic features and cytogenetic aberrations, is now widely accepted. Previous studies have shown that high histologic grade and incomplete gross resection are the most important prognostic factors for survival ...

      Known for Histologic Subtype | Retroperitoneal Liposarcoma | Recurrence Survival | Contiguous Organ Resection | Prognostic Significance
      KOL-Index: 15088

      BACKGROUND: Synovial sarcomas account for up to 10 percent of soft-tissue sarcomas and include two major histologic subtypes, biphasic and monophasic, defined respectively by the presence and absence of glandular epithelial differentiation in a background of spindle tumor cells. A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. The translocation fuses the SYT gene from chromosome 18 to either ...

      Known for Gene Fusion | Histologic Subtype | Proteins Sarcoma | Syt Ssx | Pair Female Humans
      KOL-Index: 14861

      Acinar cell carcinomas (ACCs) are rare malignant tumors of the exocrine pancreas. The specific molecular alterations that characterize ACCs have not yet been elucidated. ACCs are morphologically and genetically distinct from the more common pancreatic ductal adenocarcinomas. Instead, the morphological, immunohistochemical, and clinical features of ACCs overlap with those of another rare pancreatic neoplasm, pancreatoblastoma. We have recently demonstrated a high frequency of allelic loss ...

      Known for Allelic Loss | Pancreatic Acinar | Cell Carcinoma | Human Pair | Chromosome 11p
      KOL-Index: 14790

      PURPOSE: The prognostic significance of germline BRCA1 and BRCA2 mutations in Jewish patients with pancreatic adenocarcinoma (PAC) is unknown. Our objective was to define the prevalence of BRCA1 and BRCA2 in an unselected group of Jewish patients and to compare the clinical characteristics and overall survival (OS) of patients with resected BRCA mutation-associated PAC to PAC patients without mutations.

      PATIENTS AND METHODS: Jewish patients with PAC resected between January 1986 and ...

      Known for Pancreatic Adenocarcinoma | Brca1 Brca2 | Mutations Patients | Mutation Pac
      KOL-Index: 14776

      OBJECTIVE: To compare disease-specific survival (DSS) between the US and Korea following R0 resection for gastric carcinoma (GC).

      SUMMARY BACKGROUND DATA: Many studies have described decreased 5-year survival after curative gastrectomy for GC in the West compared with the East. Although clinicopathological presentations of GC are known to vary widely between Eastern and Western countries, including histology, tumor location, and stage at presentation, it remains unclear whether these ...

      Known for R0 Resection | United States | Gc Patients Korea | Gastric Cancer Survival | Multivariate Analysis
      KOL-Index: 14631

      BACKGROUND: Two years after undergoing resection of liver metastases from colorectal cancer, about 65 percent of patients are alive and 25 percent are free of detectable disease. We tried to improve these outcomes by treating patients with hepatic arterial infusion of floxuridine plus systemic fluorouracil after liver resection.

      METHODS: We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial ...

      Known for Colorectal Cancer | Hepatic Arterial Infusion | Systemic Therapy | Patients Resection | Liver Metastases
      KOL-Index: 14513

      PURPOSE: A previously reported randomized trial from out institution demonstrated a local control advantage to adjuvant brachytherapy (BRT) for completely resected high grade soft tissue sarcoma (STS). In recent years, BRT boost has been combined with wide field external beam radiotherapy (EBRT) for selected patients in whom the margin(s) of resection was positive. This study evaluates the impact of BRT boost plus EBRT on local control in this subset of patients and on wound complication ...

      Known for Wound Complications | Local Control | Brt Ebrt | Soft Tissue | External Beam
      KOL-Index: 13950

      Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA. Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST. It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy. To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection. ...

      Known for Acquired Resistance | Imatinib Gist | Secondary Mutations | Gastrointestinal Stromal | Kit Exon
      KOL-Index: 13941

      BACKGROUND: The INK4A and INK4B genes map to chromosome 9p21, with the INK4A gene encoding two protein products, p16 and pl9ARF. Alterations of the INK4A and INK4B genes occur frequently in certain primary malignant neoplasms. This study was undertaken to evaluate the frequency of INK4A and INK4B gene alterations in a cohort of adult soft tissue sarcomas.

      METHODS: The status of the INK4A and INK4B genes was determined in 46 soft tissue sarcomas by use of the following methods: Southern ...

      Known for Soft Tissue | P16 Genes | Ink4b Gene | Alterations Ink4a | P53 Prb

      Key People For Gastric Cancer

      Top KOLs in the world
      #1
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #2
      Jacques Ferlay
      cancer incidence global burden latin america
      #3
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #4
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #5
      David Forman
      gastric cancer helicobacter pylori eradication therapy
      #6
      Jaffer A Ajani
      gastric cancer esophageal adenocarcinoma preoperative chemoradiation

      Memorial Sloan Kettering Cancer Center, New York, NY, USA | Weill Cornell Medical College, New York, NY, USA | From the Gastric and Mixed Tumor Service, Department of Surgery (Nakauchi, Court, Coit, Brennan, Strong), Memorial Sloan Kettering Cancer C

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.